Stay updated with breaking news from Adjuvant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.
Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer.
– In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28% – – Up to 80%... | April 16, 2023
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this type
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanomaCAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE